Click for Full Press Release:
  Feb, 2007
  Jan 7, 2007
  Dec, 2006
  Feb 28, 2006
  Sept 06, 2005
  March 30, 2004
  May 30, 2001
  April 21, 2000
  August 1, 1998



 

In The News:

   Forbes
  Sunday Times
  Wall Street Journal
  Photonics Spectra
  Investor Business Daily
  New York Times
  San Francisco Chronicle


Email:
Info@Lumacare.com
Sales@LumaCare.com

Phone:
+1 949 644 0126

USA Address:
P.O. Box 2024,
Newport Beach, CA 92659

"New Throat Cancer Treatment Attacks with Beams of Light"
© The New York Times

WASHINGTON, DEC. 30 (AP)
Patients dying of throat cancer will soon be able to use light to help them swallow on their own.

The Food and Drug Adiministration on Wednesday approved Photofrin, the first of a new type of treatment that uses special drugs to make tumors light-sensitive and then sends beams of light to kill the cancer cells.

Photofrin was approved to help clear the esophagus when patients' tumors grow so big that the patient cannot swallow, but this so-called photodynamic therapy is also being tested against bladder, bronchial and other tumors.

The "attractiveness of it is it" only makes you sick where the light hits it, said Dr. Robert Temple of the Food And Drug Administration. Any tumor you can localize and shine a light on could potentially be treated this way.

But patients are vulnerable to severe sun burns until the drug wears off -- about 30 days.

The American Cancer Society estimates that esophageal cancer 12,100 Americans in 1995 and killed 10,900 them, slowly constricting their throats until they could not eat or even swallow their own saliva.

Standard therapy is to chip away at the tumor with a laser, Dr. Temple said. But patients whose tumors were to big for the laser to help have had no other options.

Photofrin, manufactured by QLT Phototherapeutics Inc. of Vancouver, British Columbia, is a chemically modified version of a substance culled from pigs' blood called potfirmer sodium.

Patients are injected with Photofrin. Several hours later, doctors thread tiny fiber-optic cables on the tumor. The light switches on the Photofrin, making it produce substances called free radicals that kill cells.

Photofrin was not studied long enough to tell if it helped patients live longer, but it did give patients a higher quality of life because they could once again swallow on their own. That benefit lasted more than 69 days for half of the patients, but QLT Phototherapeutics stopped counting them and could not say how soon after the study the patients throats reclogged, but median survival was 115 days.

 

Website Designed and Maintained by Rod Steel Designs
© 1996-2008 MBG Technologies